Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML

Slideset - Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Source: Clinical Care Options Leukemia - June 12, 2017 Category: Hematology Source Type: research